fbpx Skip to main content

On Friday May 1 Gilead’s investigational antiviral drug Remdesivir received emergency use authorization for the treatment of COVID-19. Gilead’s CEO Dan O’day indicated “We intend to get that to patients in the early part of this next week,” while on CBS’ “Face of the Nation”.

He went on to state that Gilead has donated 1.5 million vials of Remdesivir, which can treat 100,000 to 200,000 people, to the government. The federal government will distribute these treatments according to need in cities throughout the country. Treatments are expected to be in the hands of doctors and nurses in the upcoming days. According to the CDC there have been over 1.12 million confirmed cases of COVID-19 and over 65,000 deaths in the U.S.


Pharma CEO says coronavirus drug remdesivir will be available this week

CDC Cases in the U.S.

Read more:

Listen to Michelle Obama’s Message to Healthcare Workers During the COVID-19 Pandemic

You May Also Like::  Decrease Seen in Non-COVID-19-Related Hospitalizations at Peak

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More